PTCT Earnings & Financial Statements
PTC Therapeutics, Inc.
$59.67
-$0.25(-0.42%)
45
Overall
60
Value
18
Tech
57
Quality
Market Cap
$4.98B
Volume
1.51M
52W Range
$61.23 - $90.87
Target Price
$101.07
PTCT earnings and financial statements: PTC Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
PTCT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $1.73B | $806.78M | $937.82M | $698.80M | $538.59M |
| Cost of revenue | $47.01M | $57.40M | $65.49M | $44.68M | $32.33M |
| Operating income | $866.93M | -$302.57M | -$439.50M | -$447.41M | -$374.44M |
| EBITDA | $896.35M | -$111.51M | -$318.64M | -$356.00M | -$368.18M |
| Net income | $682.64M | -$363.30M | -$626.60M | -$559.02M | -$523.90M |
| EPS (diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B |
| Total liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B |
| Shareholders’ equity | -$205.31M | -$1.10B | -$818.55M | -$347.09M | $1.44M |
| Cash and equivalents | $984.65M | $779.71M | $594.00M | $279.83M | $189.72M |
| Long-term debt | $96.58M | $375.93M | $399.02M | $691.26M | $375.61M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $711.20M | -$107.69M | -$158.42M | -$356.65M | -$251.33M |
| Capital expenditure | -$299.94M | -$46.19M | -$120.62M | -$152.46M | -$85.33M |
| Free cash flow | $411.18M | -$181.94M | -$279.04M | -$509.11M | -$336.66M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PTCT | $59.67 | -0.4% | 1.51M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |